We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

Postmenopausal women with vulvovaginal atrophy treated with intravaginal prasterone for at least 12 weeks were nearly 50% ...

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

[5] Early adjuvant therapy -- replacing tamoxifen therapy with aromatase inhibitor therapy during the first 5 years after surgery; Early sequential adjuvant therapy -- sequencing of tamoxifen and ...

Compared with endocrine therapy, radiotherapy was associated with a smaller reduction in health-related quality-of-life in ...

In a long awaited approveall, The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

Considering taking supplements to treat aromatase inhibitor induced arthralgia? Below is a list of common natural remedies used to treat or reduce the symptoms of aromatase inhibitor induced ...

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...